Nirsevimab may offer infants stronger protection against severe respiratory syncytial virus than maternal vaccination, ...
A new study published in the Journal of American Medical Association showed that veterans, 60 years of age and older who got ...
A vaccine developed to tackle Streptococcus suis, an economically damaging disease endemic in the global pig population, has ...
Its proprietary and differentiated lipid nanoparticle (LNP) platform is a cornerstone in advancing next-generation messenger ...
Sanofi's acquisition of Dynavax, valued at $2.2 billion, aims to enhance its vaccine portfolio, including a promising shingles vaccine candidate, Z-1018. Z-1018 has demonstrated comparable ...
SHELTON, CONNECTICUT / ACCESS Newswire / January 13, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a ...
In a perfect world, vaccines would be a straightforward part of parenting. But in 2026, keeping your kids protected from preventable diseases means navigating medical misinformation, shifting public ...
These findings — from a blood test to improvements in drug delivery — may lead to better diagnosis and treatment of the ...
Accelerated by the COVID-19 pandemic, research is now exploring vaccines capable not only of preventing infections, but also ...
COVID-19, RSV, and influenza immunizations show continued safety and substantial effectiveness against hospitalization across ...
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately ...
Detailed price information for Biovaxys Technology Corp (BIOV-CN) from The Globe and Mail including charting and trades.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results